Wayne Leimbach, MD
Interventional Cardiology · Tulsa, OKNPI 1093785933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,830 of the $68,016 with a category attached, or 76.2%. 28 manufacturers reported payments, led by AstraZeneca at 38.9% of the total. Reporting peaked in 2024 at $19,067 and has fallen 98.3% since, to $332 in 2025. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $242.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$26K
- Lexicon Pharmaceuticals, Inc.$18K
- Esperion Therapeutics, Inc.$11K
- Medtronic$3K
- Abiomed$3K
- Edwards Lifesciences$2K
- plus $4K from 22 others
Across 56 payments — averaging $3842.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$155K
- CSL Behring$47K
- AstraZeneca$12K
- Amarin Pharma, Inc.$2K
- Abiomed$17
What the payments were for
- Speaking & faculty fees$51,83076%
- Travel & lodging$7,76811%
- Food & beverage$8,39512%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $26,442 |
| Lexicon Pharmaceuticals, Inc. | 26 | $18,415 |
| Esperion Therapeutics, Inc. | 8 | $10,874 |
| Medtronic(2 entities) | 58 | $2,845 |
| Abiomed | 21 | $2,655 |
| Edwards Lifesciences | 30 | $2,410 |
| Abbott | 31 | $1,117 |
| Novartis | 13 | $971 |
| Inari Medical, Inc. | 6 | $407 |
| Shockwave Medical, Inc | 2 | $310 |
| Boston Scientific | 9 | $190 |
| E.r. Squibb & Sons, L.L.C. | 4 | $181 |
| Penumbra, Inc. | 1 | $160 |
| Silk Road Medical, Inc. | 4 | $158 |
| ZOLL Respicardia, Inc. | 1 | $158 |
| Heartflow, Inc. | 1 | $121 |
| Merck | 2 | $120 |
| Cvrx, Inc. | 1 | $119 |
| Amgen | 5 | $103 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Philips North America LLC | 2 | $55 |
| Cardiva Medical, Inc. | 2 | $36 |
| Atricure, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| B. Braun Interventional Systems Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$26,135
- Inpefa$17,815
- NEXLIZET$10,874
- NEXLETOL$10,874
- Impella$2,235
- Resolute$1,706
- LEQVIO$832
- Edwards SAPIEN 3 Transcatheter Heart Valve$642
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$483
- FLOWTRIEVER CATHETER, S$343
- CT THROMBECTOMY SYSTEM KIT$343
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$310
- Tendyne Mitral Valve System$218
- Indigo System$160
- remede System$158
- HeartMate 3 Left Ventricular Assist Device$149
- Accent Pacemaker$144
- AMPLATZER Occluders$128
- CoreValve Evolut$123
- CAMZYOS$122
How this compares
$68,016 in reported general payments places this provider in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $270,213 |
| TracleerBosentan | 11 | $142,128 |
| EntrestoSacubitril/Valsartan | 65 | $68,813 |
| JardianceEmpagliflozin | 57 | $46,235 |
| FarxigaDapagliflozin Propanediol | 49 | $34,449 |
| Repatha SureclickEvolocumab | 40 | $28,628 |
| BrilintaTicagrelor | 35 | $24,782 |
| XareltoRivaroxaban | 14 | $22,159 |
| Praluent PenAlirocumab | 26 | $15,218 |
| MultaqDronedarone Hcl | 12 | $9,861 |
| Ezetimibe | 413 | $9,356 |
| Metoprolol Succinate | 489 | $8,572 |
| Atorvastatin Calcium | 370 | $5,255 |
| Rosuvastatin Calcium | 307 | $4,378 |
| NexletolBempedoic Acid | 11 | $4,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $971 | $68,81365 claims |
| AstraZenecaFarxiga, Brilinta | $26,442 | $59,23184 claims |
| Johnson & JohnsonXarelto | $19 | $22,15914 claims |
| Esperion Therapeutics, Inc.Nexletol | $10,874 | $4,32611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.